On Tuesday (July 22), U.S. life sciences company Danaher raised its full-year profit forecast, mainly benefiting from continued demand for bioprocessing products from pharmaceutical clients and signs of gradual recovery in the Chinese market.
According to Reuters, Danaher now expects full-year adjusted earnings per share to be between $7.70 (32.4 ringgit) and $7.80, higher than the previous estimate of $7.60 to $7.75. The company also expects third-quarter revenue to achieve low single-digit year-over-year growth.
Based on LSEG data, Danaher's second-quarter sales reached $5.94 billion, exceeding analysts' expectations of $5.84 billion.
As a life sciences company providing pharmaceutical companies with drug research and production tools and technologies, Danaher said that overall demand in the industry remains robust, with sufficient clinical trials and steady progress in new therapies.
Danaher CEO Rainer Blair pointed out that several high-dose therapies are about to face patent expiration, which is also driving growth in the bioprocessing business. The company expects this business to deliver high single-digit long-term growth.
Blair also said: "Monoclonal antibodies remain the most concentrated investment area for our customers, accounting for more than 75% of our bioprocessing revenue."
The Chinese market accounts for about 12% of Danaher's total revenue. Despite pressures in China due to changes in volume-based procurement and medical insurance payment policies, Danaher said that, apart from diagnostics, signs of recovery have begun to emerge in the Chinese market, with government support policies for the pharmaceutical and biotechnology industries gradually taking effect.
A company executive revealed in a conference call that currently, the business affected by proposed tariffs is only several hundred million dollars, lower than previously estimated.
Danaher also pointed out that due to uncertainties in research funding, demand from academia and government sectors remains weak; however, the clinical diagnostics and applied markets remain stable.
Analysts believe that Danaher's reported results were "steady," and with the Chinese market showing signs of recovery and the bioprocessing business expected to rebound in 2026, the company's growth momentum is expected to further strengthen.
According to Reuters, Danaher now expects full-year adjusted earnings per share to be between $7.70 (32.4 ringgit) and $7.80, higher than the previous estimate of $7.60 to $7.75. The company also expects third-quarter revenue to achieve low single-digit year-over-year growth.
Based on LSEG data, Danaher's second-quarter sales reached $5.94 billion, exceeding analysts' expectations of $5.84 billion.
As a life sciences company providing pharmaceutical companies with drug research and production tools and technologies, Danaher said that overall demand in the industry remains robust, with sufficient clinical trials and steady progress in new therapies.
Danaher CEO Rainer Blair pointed out that several high-dose therapies are about to face patent expiration, which is also driving growth in the bioprocessing business. The company expects this business to deliver high single-digit long-term growth.
Blair also said: "Monoclonal antibodies remain the most concentrated investment area for our customers, accounting for more than 75% of our bioprocessing revenue."
The Chinese market accounts for about 12% of Danaher's total revenue. Despite pressures in China due to changes in volume-based procurement and medical insurance payment policies, Danaher said that, apart from diagnostics, signs of recovery have begun to emerge in the Chinese market, with government support policies for the pharmaceutical and biotechnology industries gradually taking effect.
A company executive revealed in a conference call that currently, the business affected by proposed tariffs is only several hundred million dollars, lower than previously estimated.
Danaher also pointed out that due to uncertainties in research funding, demand from academia and government sectors remains weak; however, the clinical diagnostics and applied markets remain stable.
Analysts believe that Danaher's reported results were "steady," and with the Chinese market showing signs of recovery and the bioprocessing business expected to rebound in 2026, the company's growth momentum is expected to further strengthen.